文献速递胸部肿瘤放疗放疗物理与技术

PET-Plan试验RTQA结果:NSCLC同步放化疗中放疗方案依从性的影响

Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial.
PubMed 文献 · Radiother Oncol · 2021-07-24

PET-Plan是一项开放标签随机对照试验,纳入不可手术NSCLC患者,比较PET/CT引导与单纯PET引导靶区勾画并接受等毒性剂量递增同步放化疗。前瞻性RTQA按预设标准评分方案依从性,204例起始治疗患者中31例(15%)存在重大偏差,重大偏差与更差的总生存和无局部区域进展风险显著相关。

要点

  • 204例起始治疗患者中31例(15%)存在重大方案偏差。
  • 重大偏差者总生存更差(HR 2.9,95%CI 1.8-4.4,p<0.0001)。
  • 重大偏差者局部区域进展风险更高(HR 5.7,95%CI 2.7-11.1,p<0.0001)。

核心结论

  • 不依从放疗方案与更差的总生存和局部区域控制相关,结果强调RTQA的重要性。

研究设计与样本

  • 开放标签随机对照PET-Plan试验,2009年5月至2016年11月随机205例不可手术NSCLC患者,204例按方案开始治疗。
  • 前瞻性RTQA按预设标准进行个案审查,依从性评分为符合方案、轻微偏差、中等偏差和重大偏差。
  • 额外分析接受≥60 Gy的患者以排除因停止治疗带来的偏倚。

主要发现

  • 204例起始治疗患者中31例(15%)存在重大偏差。
  • 重大偏差者总生存更差(HR 2.9,95%CI 1.8-4.4,p<0.0001),局部区域进展风险更高(HR 5.7,95%CI 2.7-11.1,p<0.0001)。
  • 接受≥60 Gy亚组中上述结果仍显著。
  • 正常组织勾画和/或剂量约束存在重大偏差者总生存更差(p=0.006),但≥3级毒性发生率未更高。

关键数值与推荐

  • 重大偏差定义为RTQA预设标准下的major deviation(maD)。
  • 依从性分级包括符合方案(pP)、轻微偏差(miD)、中等偏差(inD)和重大偏差(maD)。

临床怎么用

  • NSCLC根治性同步放化疗中应重视放疗方案依从性,正常组织勾画和剂量约束的重大偏差与更差生存相关。
  • 前瞻性RTQA个案审查可用于识别重大方案偏差并指导质量改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The success of intensification and personalisation of the curative treatment of non-small cell lung cancer (NSCLC) is strongly associated with the precision in radiotherapy. Here, we evaluate the impact of radiotherapy protocol adherence in a prospective multicentre trial. METHODS: In the open-label, randomised, controlled PET-Plan trial, patients with inoperable NSCLC were randomized at a 1:1 ratio regarding the target volume delineation informed by 1F-FDG PET and CT plus elective nodal irradiation (arm A) or target volumes informed by PET alone (arm B) and received iso-toxically dose-escalated concurrent chemoradiation. The prospectively organised quality assurance program (RTQA) included individual case review by predefined criteria. For evaluation, protocol adherence was scored as per protocol (pP), with minor (miD), intermediate (inD) and major (maD) deviations. In order to exclude biases through patients who discontinued treatment, patients who received ≥60 Gy were additionally analysed. RESULTS: Between 05/2009-11/2016, 205 patients were randomized, 204 patients started treatment according to protocol of which 31 (15%) patients had maD. Patients with maD had an inferior overall survival (OS) (HR 2.9, 95% CI 1.8-4.4, p < 0.0001) and a higher risk of loco-regional progression (HR 5.7, 95% CI 2.7-11.1, p < 0.0001). These results were significant also in the subgroup of patients receiving ≥ 60 Gy. Patients with maD concerning normal tissue delineation and/or dose constraints had a worse OS (p = 0.006) although no higher incidence of grade ≥ 3 toxicities. CONCLUSIONS: Non-adherence to the radiotherapy protocol was associated with an inferior OS and loco-regional control. These results underline the importance of RTQA.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gkika E, Schimek-Jasch T, Kremp S, et al. Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. Radiother Oncol. 2021. PMID: 34311004. doi:10.1016/j.radonc.2021.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。